Biotech Values

[DewDiligence]

Dew likes EXAS enough to select it as a pick in the 2013 [Silicon Investor] charity contest. But does he like it enough to put real money into it at this price?

No—the current valuation has too high a probability of success baked in for the DeeP-C study, IMO. Although the study has a very good chance to succeed, it’s not a lock; failure—or even mixed results—would be a debacle of immense proportions insofar as the company has nothing else to offer.